Alnylam Pharmaceuticals Inc (ALNY) is a pioneering American biopharmaceutical company specializing in RNA interference (RNAi) therapeutics for the treatment of rare genetic diseases and other serious medical conditions. Operating in the healthcare and biotechnology sector, the company has successfully transitioned from a research-stage organization to a commercial-stage pharmaceutical company with multiple FDA-approved therapies generating significant revenue growth. This analysis provides a comprehensive, fact-based examination of Alnylam’s financial position, ownership structure, and realistic share price projections through 2030 based on current market data and publicly available financial metrics.
Alnylam Pharmaceuticals Inc: Company Overview
- Founded in 2002 by Phillip Sharp, Paul Schimmel, David Bartel, Thomas Tuschl, and Phillip Zamore in Cambridge, Massachusetts
- Headquarters: Cambridge, Massachusetts, United States
- Core Business Segments: Rare genetic disease therapeutics, cardiovascular and metabolic disease treatments, and central nervous system disorders
- Key Products/Services: ONPATTRO (patisiran) for hereditary transthyretin-mediated amyloidosis, AMVUTTRA (vutrisiran) for ATTR amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, OXLUMO (lumasiran) for primary hyperoxaluria type 1, and Leqvio (inclisiran) for hypercholesterolemia
- Major Clients/Markets: Patients with rare genetic diseases, healthcare providers, hospitals, and pharmaceutical partners across North America, Europe, and the Asia-Pacific regions
- Competitive Edge: Proprietary RNAi technology platform, extensive intellectual property portfolio, first-mover advantage in RNAi therapeutics, strong clinical development pipeline, and strategic partnerships with major pharmaceutical companies
- Ownership Structure: Publicly held biotechnology company with strong institutional ownership and a professional management team maintaining a strategic focus on innovation and commercial execution
Alnylam Pharmaceuticals Inc: Key Financial Snapshot
| Metric | Value (as of February 2026) |
|---|---|
| Market Cap | $32.81 Billion |
| Current Share Price | $254.08 |
| P/E Ratio (TTM) | Not applicable (negative EPS) |
| P/B Ratio | 489.05 |
| Book Value per Share (TTM) | $0.52 |
| EPS (TTM) | -$2.18 |
| ROE | Not applicable (negative earnings) |
| ROIC | Not applicable (negative earnings) |
| Dividend Yield | 0.00% |
| Sales Growth (TTM) | 25.8% |
| Profit Growth (TTM) | Not applicable (loss) |
| Total Cash | $2.69 Billion |
| Total Debt | $1.12 Billion |
| Par Value | $0.01 per share |
Alnylam Pharmaceuticals Inc Share Price Target Forecast (2026–2030)
| Year | Low Target | Base Target | High Target |
|---|---|---|---|
| 2026 | $350 | $420 | $490 |
| 2027 | $400 | $480 | $560 |
| 2028 | $450 | $540 | $630 |
| 2029 | $500 | $600 | $700 |
| 2030 | $550 | $660 | $770 |
Year-on-Year Forecasts
Alnylam Pharmaceuticals Inc Share Price Target 2026
| Share Price Target 1 | Share Price Target 2 |
|---|---|
| $350 | $490 |
- Execution on strong earnings recovery with the current year EPS estimate of $2.46, representing the transition from losses to profitability
- Operating margin expansion as commercial products achieve scale and R&D investments begin to generate returns
- Analyst consensus price target of $484.71 from 31 analysts, with a range of $351-$580, providing near-term guidance
Alnylam Pharmaceuticals Inc Share Price Target 2027
| Share Price Target 1 | Share Price Target 2 |
|---|---|
| $400 | $560 |
- Expected acceleration in revenue from late-stage pipeline assets, including vutrisiran for ATTR cardiomyopathy and fitusiran for hemophilia
- Continued expansion of commercial footprint in international markets is driving incremental revenue growth
- Potential for improved free cash flow generation as the business scales with minimal capital expenditure requirements relative to revenue
Alnylam Pharmaceuticals Inc Share Price Target 2028
| Share Price Target 1 | Share Price Target 2 |
|---|---|
| $450 | $630 |
- Full realization of next-generation RNAi therapeutics launches and market penetration
- Expansion into adjacent therapeutic areas including cardiovascular disease and central nervous system disorders
- Potential for margin improvement as the company achieves greater operational scale and efficiency
Alnylam Pharmaceuticals Inc Share Price Target 2029
| Share Price Target 1 | Share Price Target 2 |
|---|---|
| $500 | $700 |
- Established market leadership position in RNAi therapeutics with significant competitive moat and pricing power
- Continued strong cash generation with predictable revenue streams from established commercial products
- Potential for improved return on invested capital as the company achieves greater operational scale and efficiency
Alnylam Pharmaceuticals Inc Share Price Target 2030
| Share Price Target 1 | Share Price Target 2 |
|---|---|
| $550 | $770 |
- Mature business model with predictable revenue streams from established commercial portfolio and late-stage pipeline assets
- Potential for improved profitability metrics as the company optimizes its cost structure and operational efficiency
- Continued innovation in RNAi technology maintaining competitive advantage in the rapidly evolving biotechnology landscape
Alnylam Pharmaceuticals Inc Share Price Target 2035
| Share Price Target 1 | Share Price Target 2 |
|---|---|
| $750 | $1,050 |
- Potential expansion into gene editing technologies and next-generation RNA therapeutics
- Established global presence with penetration into emerging biotechnology markets
- Long-term demographic trends favoring personalized medicine and targeted therapies
Alnylam Pharmaceuticals Inc Share Price Target 2040
| Share Price Target 1 | Share Price Target 2 |
|---|---|
| $950 | $1,350 |
Note: Projections beyond 2030 become increasingly speculative due to changing regulatory environments, technological disruption, and unpredictable market conditions. These targets represent potential scenarios based on the current business trajectory but should be viewed with appropriate caution.
Alnylam Pharmaceuticals Inc Share Price Target 2050
| Share Price Target 1 | Share Price Target 2 |
|---|---|
| $1,200 | $1,700 |
Note: Forecasts extending to 2050 are highly speculative and subject to significant uncertainty. Technological breakthroughs, competitive disruptions, or regulatory shifts could substantially alter the company’s trajectory over such an extended timeframe.
Alnylam Pharmaceuticals Inc: Shareholding Pattern
| Category | Percentage Holding |
|---|---|
| Institutional Investors | 91.25% |
| Insiders | 2.15% |
| Retail/Public | 6.60% |
Top 10 Institutional Shareholders
| Shareholder Name | Percentage Ownership | Shares Held |
|---|---|---|
| Vanguard Group Inc | 9.85% | 12,450,000 |
| BlackRock Inc | 8.12% | 10,260,000 |
| State Street Corporation | 5.24% | 6,620,000 |
| Fidelity Management & Research | 4.38% | 5,530,000 |
| Capital Research and Management Company | 3.65% | 4,610,000 |
| Price T Rowe Associates Inc | 2.98% | 3,770,000 |
| Wellington Management Company | 2.45% | 3,100,000 |
| Geode Capital Management LLC | 1.87% | 2,360,000 |
| Norges Bank Investment Management | 1.56% | 1,970,000 |
| Morgan Stanley | 1.32% | 1,670,000 |
Alnylam Pharmaceuticals Inc: Strengths vs Risks
Strengths:
- Strong revenue growth of 25.8% with multiple FDA-approved commercial products generating increasing sales
- Extensive late-stage pipeline with multiple assets in Phase III clinical trials, including vutrisiran for ATTR cardiomyopathy and fitusiran for hemophilia
- Proprietary RNAi technology platform creating a significant competitive moat and intellectual property protection
- Strong cash position of $2.69 billion supporting continued R&D investment and commercial expansion
- Strategic partnerships with major pharmaceutical companies, including Novartis, Regeneron, and Roche, providing validation and financial support
Risks:
- Elevated valuation metrics with a P/B ratio of 489.05 and negative profitability, making the stock vulnerable to clinical trial failures or regulatory setbacks
- High debt-to-equity ratio of 4,089.28%, creating financial leverage concerns despite a strong cash position
- Intense competition from emerging RNAi companies and traditional pharmaceutical approaches in rare disease markets
- Regulatory scrutiny and approval risks for pipeline assets, with potential delays or rejections impacting growth trajectory
- Limited dividend income for income-focused investors as the company reinvests all earnings into growth initiatives and R&D
Investment Suitability
| Factor | Assessment |
|---|---|
| Risk Profile | High |
| Time Horizon | Long-term (5+ years) |
| Volatility | High |
| Dividend/Income | None (growth and capital appreciation focus) |
| Ideal Investor | Growth-oriented investors with high risk tolerance seeking exposure to biotechnology innovation and rare disease therapeutics |
FAQs
The realistic share price target range for Alnylam Pharmaceuticals in 2026 is between $350 and $490, depending on execution against commercial growth initiatives and pipeline advancement.
The projected share price target range for Alnylam Pharmaceuticals in 2030 is between $550 and $770, assuming continued strong revenue growth and successful pipeline development.
Long-term projections beyond 2030 become increasingly speculative due to changing regulatory environments, technological disruption, and unpredictable market conditions. While potential scenarios suggest ranges of $950-$1,350 for 2040 and $1,200-$1,700 for 2050, these should be viewed with appropriate caution given the extended timeframe.
Alnylam Pharmaceuticals is a publicly traded company with approximately 91.25% institutional ownership, significant insider holdings of 2.15%, and the remaining 6.60% held by retail investors. The top institutional holders include Vanguard Group, BlackRock, and State Street Corporation.
No, Alnylam Pharmaceuticals does not currently pay dividends as the company reinvests all earnings into research and development, clinical trials, and commercial expansion efforts.
Recent share price fluctuations may be attributed to clinical trial results, regulatory developments, competitive pressures in the biotechnology sector, or broader market volatility affecting growth stocks.
Alnylam Pharmaceuticals is not debt-free and maintains significant debt of $1.12 billion against $2.69 billion in cash, resulting in a net cash position of approximately $1.57 billion, though the elevated debt-to-equity ratio of 4,089.28% reflects the capital-intensive nature of biopharmaceutical development.
Final Verdict
Alnylam Pharmaceuticals presents a compelling high-growth investment opportunity with strong revenue momentum, an extensive late-stage pipeline, and a pioneering RNAi technology platform. The company has successfully transitioned from research to commercial operations while maintaining significant growth potential through its development pipeline. However, investors must carefully consider the elevated valuation multiples, high financial leverage, and inherent risks associated with biotechnology development, including clinical trial failures and regulatory setbacks. The stock may appeal to growth-oriented investors with long-term horizons and high risk tolerance seeking exposure to innovative biotechnology, though those with lower risk tolerance should exercise caution given the current valuation levels and sector volatility.
Sources
- Yahoo Finance – Financial metrics, market data, and company fundamentals
- MarketWatch – Analyst estimates, price targets, and consensus recommendations
- Investing.com – News updates, analyst ratings, and market analysis
Hi, I’m Raj Mittal, a stock market content writer focused on company analysis, share price trends, and fundamental research. I create simple, research-based insights to help investors make smarter market decisions.
